Covishield vaccine produced more antibodies than Covaxin, according to a preliminary study by Coronavirus Vaccine-induced Antibody Titre. The study was conducted on healthcare workers who have received both doses of either of the two vaccines.
News agency ANI has reported that seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients compared to Covaxin after the first dose, the study claimed.
The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.
It said that both vaccines - Covishield and Covaxin - elicited a good response after two doses, but antibodies rate was significantly higher in Covishield.